REPORTING: Trump vs. Pharma?

  1. Tariffs Won't Stop Drug-Candidate Licensing From China Biotechs 4/23/2025

    According to Global Data, the total deal value of U.S. licensing of innovator drug candidates from Chinese biopharma companies has surged since 2020. This is an area way upstream of the current tariff focus on manufacturing. But how this R&D trend and those tariffs play out will impact your U.S.-based CDMOs.

  2. CDMOs Bet Big On Asia Expansion. Can Trump Reverse The Tide? 2/20/2025

    Facility investments by CDMOs continue to be magnetized to Asia. Recent examples abound. Chief Editor Louis Garguilo details some of those, and discusses whether, for example, a President Trump-intensified focus on increasing manufacturing in the U.S. can change this. Will your outsourcing in 2025 change direction? The answer may surprise you.

  3. What If The Trump Tariff Strategy Works? 4/8/2025

    Doom and gloom in the drug development and manufacturing supply chain.  Predictions of disruptions and displacements. The Trump tariff ploy will fail, and costs/prices will skyrocket. But have you considered this “risk”? The tariff tantrum lowers national export/import duties for the entire globe.